About Cardurion
Cardurion is a company based in Boston (United States) founded in 2017.. Cardurion has raised $270 million across 5 funding rounds from investors including Fidelity Investments, Farallon Capital Management and Bain Capital Private Equity. Cardurion offers products and services including PDE9 Inhibitor and CaMKII Inhibitor. Cardurion operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$270 M (USD)
in 5 rounds
-
Latest Funding Round
$260 M (USD), Series B
Jul 10, 2024
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cardurion
Cardurion offers a comprehensive portfolio of products and services, including PDE9 Inhibitor and CaMKII Inhibitor. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits PDE9 to treat chronic heart failure in patients.
Inhibits CaMKII for managing arrhythmias and related diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Cardurion
Cardurion has successfully raised a total of $270M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $260 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $260.0M
-
First Round
First Round
(04 Apr 2017)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series B - Cardurion | Valuation | Ascenta Capital | |
| Dec, 2022 | Amount | Debt – Conventional - Cardurion | Valuation |
investors |
|
| Oct, 2021 | Amount | Series B - Cardurion | Valuation | Bain Capital Life Sciences , Bain Capital Private Equity |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cardurion
Cardurion has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Farallon Capital Management and Bain Capital Private Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ascenta Capital is focused on biopharma investment and growth.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cardurion
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cardurion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cardurion Comparisons
Competitors of Cardurion
Cardurion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cardurion
Frequently Asked Questions about Cardurion
When was Cardurion founded?
Cardurion was founded in 2017.
Where is Cardurion located?
Cardurion is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Cardurion a funded company?
Cardurion is a funded company, having raised a total of $270M across 5 funding rounds to date.
What does Cardurion do?
Cardurion was founded in 2017 and is located in Boston, United States. Therapeutics targeting heart and cardiovascular diseases are developed within the biotechnology sector. Operations center on clinical-stage drug programs, including the proprietary CRD-733, a PDE-9 inhibitor designed to enhance cardiac function and mitigate dysfunction in heart failure patients. Focus remains on advancing treatments for cardiovascular conditions through targeted inhibition mechanisms.
Who are the top competitors of Cardurion?
Cardurion's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
What products or services does Cardurion offer?
Cardurion offers PDE9 Inhibitor and CaMKII Inhibitor.
Who are Cardurion's investors?
Cardurion has 13 investors. Key investors include Fidelity Investments, Farallon Capital Management, Bain Capital Private Equity, Blue Owl, and Ascenta Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.